We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.

I Agree

You are here: Industry Insights > benralizumab

News List

AstraZeneca’s Asthma drug Benralizumab gets marketing approval from DCGI expresspharma
December 23, 2020
Fasenra is an add-on maintenance treatment for patients with severe eosinophilic asthma.
AstraZeneca Pharma India gets DCGI nod for benralizumab injection, Fasenra expresspharma
December 22, 2020
It is indicated as an add-on maintenance treatment for severe asthma with an eosinophilic phenotype in adult patients.
Benralizumab not effective reducing exacerbations in moderate to very severe COPD worldpharmanews
May 24, 2019
More than 15.3 million people in the U.S. suffer from chronic obstructive pulmonary disease (COPD), which is the third leading cause of death in this country, according to the American Lung Association.
NICE backs AZ’ asthma biologic Fasenra pharmatimes
July 17, 2018
AstraZeneca’s biologic Fasenra will likely be funded on the NHS as a treatment for people with severe eosinophilic asthma.